Preclinical investigations of the efficacy of the glutaminase inhibitor CB-839 alone and in combinations in chronic lymphocytic leukemia
IntroductionChronic lymphocytic leukemia (CLL) cells are metabolically flexible and adapt to modern anticancer treatments. Bruton tyrosine kinase (BTK) and B-cell lymphoma-2 (BCL-2) inhibitors have been widely used to treat CLL, but CLL cells become resistant to these treatments over time. CB-839 is...
Main Authors: | Natalia Timofeeva, Mary L. Ayres, Natalia Baran, Janice M. Santiago-O’Farrill, Gamze Bildik, Zhen Lu, Marina Konopleva, Varsha Gandhi |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-05-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1161254/full |
Similar Items
-
Targeting MCL-1 protein to treat cancer: opportunities and challenges
by: Shady I. Tantawy, et al.
Published: (2023-07-01) -
Ibrutinib in the Treatment of Solid Tumors: Current State of Knowledge and Future Directions
by: Katarzyna Szklener, et al.
Published: (2022-04-01) -
Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective
by: Chiara Brullo, et al.
Published: (2021-07-01) -
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia
by: Elizabeth M. Muhowski, et al.
Published: (2022-11-01) -
Targeting Bruton Tyrosine Kinase: A novel strategy in the treatment of B-cell lymphomas
by: Sklavenitis-Pistofidis R., et al.
Published: (2017-06-01)